{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:43:08Z","timestamp":1777992188477,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced non-small-cell lung cancer (NSCLC) is challenging because there is no randomized controlled trial has been reported. The value of neoadjuvant and adjuvant targeted therapy remains unclear. Herein, we show that systemic treatment with ALK inhibitor crizotinib before surgery can provide the potential to cure the initially inoperable tumor. A 27-year-old man was diagnosed with a stage IIIAcT3N2M0 (7<jats:sup>th<\/jats:sup>UICC\/AJCC) upper left lung adenocarcinoma harboring EML4-ALK fusion gene. Clinically, the patient had a large primary lesion adjacent to the pericardium and regional lymph node metastasis at the ipsilateral mediastinum. Poor tumor response was observed after 3 cycles of chemotherapy (gemcitabine plus cisplatin), and upon multidisciplinary discussion, the patient was started with 250 mg crizotinib twice daily. Successive clinical examinations showed a progressive reduction of the lesions. After 2 months of therapy, the patient was downstaged to cT2aN2M0, then video-assisted thoracic surgery was performed and the final histopathological stage was ypT2aN2M0. The treatment with crizotinib (250 mg, qd) was continued more than 30 months post surgery and stopped until intracranial oligometastasis. The patient\u2019s overall survival (OS) time is 68 months at last follow-up. This case presented here supports the use of neoadjuvant and adjuvant treatment with ALK inhibitors in ALK positive locally advanced NSCLC.<\/jats:p>","DOI":"10.3389\/fonc.2021.655856","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T05:40:55Z","timestamp":1615959655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiao-Hong","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Jiang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Yin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Qiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Zhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/S0169-5002(01)00356-7","article-title":"Staging of non-small cell lung cancer: consensus, controversies and challenges","volume":"34","author":"van Meerbeeck","year":"2001","journal-title":"Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2009.n.025","article-title":"Predictors of Long-Term Survival in Patients with Lung Cancer Included in the Randomized Spanish Lung Cancer Group 0008 Phase II Trial Using Concomitant Chemoradiation with Docetaxel and Carboplatin plus Induction or Consolidation Chemotherapy","volume":"10","author":"Garrido","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in UntreatedEGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): A randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II\u2013IIIA (N1\u2013N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Resp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1538-7445.AM2012-5593","article-title":"Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Trans Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00109-014-1165-y","article-title":"Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer","volume":"92","author":"Gower","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0142-z","article-title":"Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer","volume":"73","author":"Frampton","year":"2013","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a Phase III Comparison of\u00a0First-Line Crizotinib versus Chemotherapy in\u00a0East Asian Patients with ALK-Positive Advanced Non\u2013Small Cell Lung Cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12957-015-0480-2","article-title":"Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case","volume":"13","author":"Kaseda","year":"2015","journal-title":"World J Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.161","article-title":"Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement","volume":"14","author":"Zhang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1320","article-title":"P1.18-04 Neoadjuvant Ceritinib for Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: SAKULA Trial","volume":"14","author":"Zenke","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.903528","article-title":"Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer","volume":"18","author":"Dumont","year":"2017","journal-title":"Am J Case Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000406","article-title":"Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non\u2013Small-Cell Lung Cancer Using the National Cancer Database","volume":"10","author":"Corso","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000411","article-title":"Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base","volume":"10","author":"Mikell","year":"2015","journal-title":"J Thorac Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.655856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T05:40:58Z","timestamp":1615959658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.655856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":26,"alternative-id":["10.3389\/fonc.2021.655856"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.655856","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"article-number":"655856"}}